生物分子模拟论坛

 找回密码
 立即注册

QQ登录

只需一步,快速开始

扫一扫,访问微社区

查看: 1631|回复: 3

[药物研发新闻] Ponatinib又一激酶抑制剂药物上市(2012年12月14号)

[复制链接]
发表于 2012-12-17 22:13:55 | 显示全部楼层 |阅读模式

马上注册,结交更多好友,下载更多分子模拟资源。

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
本帖最后由 中科院-石头 于 2012-12-17 22:15 编辑

Ponatinib.jpg
The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.
Iclusig is being approved more than three months ahead of the product’s prescription user fee goal date of March 27, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed the Iclusig drug application under the agency’s priority review program, which provides for an expedited six-month review for drugs that may provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.
Iclusig blocks certain proteins that promote the development of cancerous cells. The drug is taken once a day to treat patients with chronic, accelerated, and blast phases of CML and Ph+ ALL whose leukemia is resistant or intolerant to a class of drugs called tyrosine kinase inhibitors (TKIs). Iclusig targets CML cells that have a particular mutation, known as T315I, which makes these cells resistant to currently approved TKIs.
“The approval of Iclusig is important because it provides a treatment option to patients with CML who are not responding to other drugs, particularly those with the T315I mutation who have had few therapeutic options,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research. “Iclusig is the third drug approved to treat CML and the second drug approved to treat ALL this year, demonstrating FDA’s commitment to approving safe and effective drugs for patients with rare diseases.”
The FDA approved Bosulif (bosutinib) in September 2012 and Synribo (omacetaxine mepesuccinate) in October 2012 to treat various phases of CML. Marqibo (vincristine sulfate liposome injection) was approved in August 2012 to treat Philadelphia chromosome negative ALL.
Iclusig is being approved under the agency’s accelerated approval program, which provides patients earlier access to promising new drugs while the company conducts additional studies to confirm the drug’s clinical benefit and safe use. The therapy was granted an orphan product designation because it is intended to treat a rare disease or condition.
Iclusig’s safety and effectiveness were evaluated in a single clinical trial of 449 patients with various phases of CML and Ph+ ALL. All participants were treated with Iclusig.
The drug’s effectiveness was demonstrated by a reduction in the percentage of cells expressing the Philadelphia chromosome genetic mutation found in most CML patients, major cytogenetic response (MCyR). Fifty-four percent of all patients and 70 percent of patients with the T315I mutation achieved MCyR. The median duration of MCyR had not yet been reached at the time of analysis.
In accelerated and blast phase CML and Ph+ ALL, Iclusig’s effectiveness was determined by the number of patients who experienced a normalization of white blood cell counts or had no evidence of leukemia (major hematologic response or MaHR). Results showed:
  • 52 percent of patients with accelerated phase CML experienced MaHR for a median duration of 9.5 months;
  • 31 percent of patients with blast phase CML achieved MaHR for a median duration of 4.7 months; and
  • 41 percent of patients with Ph+ ALL achieved MaHR for a median duration of 3.2 months.
Iclusig is being approved with a Boxed Warning alerting patients and health care professionals that the drug can cause blood clots and liver toxicity. The most common side effects reported during clinical trials include high blood pressure, rash, abdominal pain, fatigue, headache, dry skin, constipation, fever, joint pain, and nausea.
Iclusig is marketed by ARIAD Pharmaceuticals, based in Cambridge, Mass. Bosulif is marketed by New York City-based Pfizer, and Synribo is marketed by Frazer, Pa.-based Teva Pharmaceuticals. Marqibo is marketed by Talon Therapeutics Inc. based in South San Francisco, Calif.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332252.htm
http://en.wikipedia.org/wiki/Ponatinib

PS: Ponatinib能够有效克服T315I耐药突变(此前的Imatinib, Dasatinib, Nilotinib均无效),治疗慢性粒白血病。之所以能克服耐药是因为通过炔键,规避了I315的残基位阻,这一设计思路可以看做是解决gatekeeper耐药突变的一个经典范例。针对该药物的me-too分子主要集中在左边与hinge区结合的杂环,以及中间炔键的有效替换,以及右边亲水域结合链的替换,尤其,苯环上的角甲基,对于Bcr-Abl的选择至关重要。


评分

参与人数 1金币 +10 收起 理由
SYPHU_me + 10 赞一个!

查看全部评分

发表于 2013-7-19 20:18:15 | 显示全部楼层
   学习学习
发表于 2013-11-28 15:03:27 | 显示全部楼层
嗯。这个化合物很有代表性。
不过前一段出了点问题,使用中发现了些很严重的血管不良事件,包括致命性血栓生成等等。上个月底FDA终于使得ARIAD公司不得不宣布停止在美的相关销售及推广活动,后续其它临床研究也受到了影响。最新消息也有利好,在欧洲的监管部门看来,用这个药相关病人还是有获益的,前几天宣布可以继续在欧洲销售(在更严格的相关措施下)。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

QQ|分迪科技|手机版|Archiver|生物分子模拟论坛 ( 蜀ICP备14009200号-3

GMT+8, 2018-1-16 21:45 , Processed in 0.227448 second(s), 35 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表